Achilles is mainly engaged in the manufacture and sale of shoes, plastic products and industrial materials. Along with its subsidiaries and associated companies, Co.'s principal business segments are shoes, plastic products, and industrial material. Co.'s principal products are shoes such as "ACHILLES SORBO," "SYUNSOKU LemonPie, " "SYUNSOKU DANCE," "SYUNSOKU BABY," and "SPALDING"; synthetic leather "Super Carbon" for car seats, paste leather "Partner" for car seats, and paste leather for car door molds; and ranging from interior materials that enhance the look of the home to insulating materials and rigid fluorocarbon-free urethane foam insulating materials.

GeNeuro SA. Geneuro SA is a Switzerland-based clinical stage pharmaceutical company that develops treatments for autoimmune diseases, including multiple sclerosis (MS) and other diseases associated with human endogenous retroviruses (HERV). The Company's main product, GNbAC1, is a humanized monoclonal antibody that is in clinical development phase IIb. GNbAC1 neutralizes the MSRV-Env protein rather than targeting the patient's immune system, and slows down or even halts the progression of multiple sclerosis. The Company's main shareholders are Eclosion2, a launching platform for new companies in the life sciences field, bioMerieux SA, which specializes in vitro diagnostics for medical and industrial applications, Institut Merieux, a private equity company, and Servier, an independent French pharmaceutical company.

Onxeo is a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, driven by high therapeutic demand in one of the fastest growing segments of the pharmaceutical industry. Co.'s orphan oncology product portfolio comprises 3 products (Livatag®, Beleodaq®, and AsiDNA™), ranging from preclinical to advanced phases of clinical development.